Probenecid-Boosted Tenofovir: A PBPK model informed strategy for on-demand HIV pre-exposure prophylaxis.
Multiple doses of tenofovir disoproxil fumarate (TDF) together with emtricitabine is effective for HIV Pre-Exposure Prophylaxis (PrEP). TDF is converted to tenofovir (TFV) in circulation, which is subsequently cleared via tubular secretion by OAT1 and OAT3. Using in vitro kinetic parameters for TFV and the OAT1 and OAT3 inhibitor probenecid, a bottom-up PBPK model was successfully developed for the first time that accurately describes the probenecid-TFV interaction. This model predicted an increase in TFV plasma exposure by 60%, which was within 15% of the observed clinical PK data, and a 3-fold decrease in renal cells exposure following coadministration of a 600mg TDF dose with 2g probenecid. Compared to multiple-dose regimens, a single-dose PRO-boosted TDF regimen may be effective for HIV PrEP and improve adherence and safety by minimizing TFV-induced nephrotoxicity by reducing TFV accumulation in renal cells.